ARTICLE | Clinical News

AGS-004: Updated Phase IIa data

August 2, 2010 7:00 AM UTC

Updated data from the ongoing, open-label, Canadian Phase IIa CTN 239 trial in 22 patients who completed a 12-week structured antiretroviral therapy (ART) treatment interruption period showed that the mean viral load reduction for responders to AGS-004 (n=14) was 1.3 log10 copies/mL compared to pre-ART viral load average. Mean time to detectable viral rebound and median time to peak viral load during ART interruption was 3.77 and 8 weeks, respectively. The mean duration of patients' ART interruption period was 25.1 weeks. The trial enrolled chronically infected patients who were receiving ART and added AGS-004 once a month for 4 months. Then ART was discontinued, and patients received 2 additional doses of AGS-004 one week apart. Data were presented at the International AIDS Conference in Vienna. ...